MODEL VERDICT
Zentalis Pharmaceuticals, Inc. (ZNTL)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 8, 2026 | NEUTRAL | 0.14 | $4.41 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.14 | $4.64 | Below threshold | -12.7% |
| Apr 16, 2026 | NEUTRAL | 0.14 | $5.36 | Below threshold | -24.4% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 6 industry peers | $2.26 | -48.8% | 4% | B | Data |
| Price / Sales 6 industry peers | $2.39 | -45.8% | 3% | B | Model Driven |
| Weighted Output Blended model output | $2.04 | -53.8% | 100% | 55 | SIGNIFICANTLY OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.40 | 2.47 | 0.64 | 9.95 | 3.81 |
| P/B Ratio | 4.32 | 2.45 | 0.64 | 9.85 | 3.74 |
Based on our peer multiples analysis with 4 valuation metrics, the model estimates ZNTL's fair value at $2.04 vs the current price of $4.41, implying -53.8% downside potential. Model verdict: Significantly Overvalued. Confidence: 55/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $2.04 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $1.63 (P10) to $3.00 (P90), with a median of $2.31.
ZNTL's current P/E of -1.9x compares to the industry median of 18.1x (2 peers in the group). This represents a -110.5% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
12 analysts cover ZNTL with a consensus rating of Buy. The consensus price target is $6.00 (range: $2.00 — $10.00), implying +36.1% upside from the current price. Grade breakdown: Strong Buy (0), Buy (8), Hold (4), Sell (0), Strong Sell (0).
The model confidence score is 55/100, based on: data completeness (6), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for ZNTL.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.